Another therapeutic approach is to induce HRD in otherwise HRR-competent cancersby altering the tumour microenvironment through hypoxia, or to combine PARPinhibitors with agents that can downregulate HRR, such as vascular endothelialgrowth factor (VEGF) inhibitors. The gene discussed is VEGFA; the disease is neoplasm.